Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie

 
• By Anju Ghangurde
  
Skydivers
LUPIN HAS LICENSED ITS EARLY STAGE ONCOLOGY ASSET TO ABBVIE
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip